Bone Marrow Transplantation The transfer of living cells, tissues, or organs from a donor to a recipient, with the.

Slides:

Advertisements

Similar presentations

Cord Blood Transplantation: Umbilical Blood As Hematopoietic Stem Cell Source Analysis of theoretical/clinical advantages/disadvantages Comparison with.

Advertisements

Hematopoietic Stem Cell Transplantation Lynn Savoie September 30, 2006.

Congenital Neutropenia: Making the Decision to Transplant John E. Levine, MD, MS University of Michigan Blood and Marrow Transplantation Program.

A Project on Bone marrow HASEEB TANVEER/ FOZIA TANVEER

Questions and Answers about Bone Marrow Stem Cell Transplantation prepared by the Armenian Bone Marrow Donor Registry.

Blood and Marrow Transplant: The basics…what you need to know Resident Education Lecture Series.

Hematopoietic stem cell transplantation

BLOOD TRANSFUSION SUPPORT IN STEM CELL TRANSPLANT

Bone Marrow Transplant in Oncology. Source Pathology  Treat Leukemia by chemotherapy  Regeneration of normal marrow  Chemotherapy alone cannot eliminate.

Blood and marrow stem cell transplantation A.Basi ADULT HEMATOLOGIST,ONCOLOGIST IRAN UNIVERSITY OF MEDICAL SCIENCES.

Hematopoietic Stem Cell Transplantation (HSCT) Overview Willis H Navarro, MD Medical Director, Transplant Services, NMDP Associate Clinical Professor,

CHIMERISM & DLI Dr. Serdar ŞIVGIN Kayseri Feb, 2011.

Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

Jeffrey Schriber, M.D. FRCP (c) Medical Director Cancer Transplant Institute Virginia G. Piper Cancer Center Everything You Ever Wanted to Know About Transplant.

Transplantation Rejection of foreign tissue grafts is due to immune responses to alloantigens on the graft Blood group antigens Polymorphic MHC antigens.

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2010 CIBMTR Summary Slides SUM10_1.ppt.

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2011 Summary Slides Worldwide SUM-WW11_1.ppt.

Building Canada’s National Public Cord Blood Bank.

Introduction to Haematopoietic Stem Cell Transplantation (HSCT) Covenant Health System HSCT Program Lubbock, Texas April 4, 2007.

Bone Marrow Transplantation The transfer of living cells, tissues, or organs from a donor to a recipient, with the.

Why Special Blood Products?

Hematopoietic stem cell transplantation- HSCT. Principle of HSCT Myeloablation and eradication of residual disease with hogh dose conditioning regimen.

DONOR LYMPHOCYTE INFUS I ON (DLI) Dr. Serdar ŞIVGIN February 2011 Kayseri.

Immunology of transplantation. Types of transplantation Autotransplantation –within one organism Allotransplantation- between one species Xenotransplantation-

G. S / AIH 2006 Graft-versus-Host disease Physiopathology Gérard Socié, MD PhD Hospital Saint Louis Translating experimental into clinical knowledge.

Tolerance Induction Dr. S. Strober Stanford University.

Bone marrow Transplant in Paediatric Haematology

HAEMATOPOIETIC STEM ELL TRANSPLANTATION (HSCT) A process in which abnormal, malignant, or non- functioning marrow cells are replaced with normal marrow.

Autoimmune Diseases How Do the Immune Cells of the Body Know What to Attack and What Not To Attack ?

HAPLOIDENTICAL STEM CELL TRANSPLANT

Hematopoietic Stem Cell Transplantation (HSCT)

HAEMATOPOIETIC STEM ELL TRANSPLANTATION (HSCT) A process in which abnormal, malignant, or non- functioning marrow cells are replaced with normal marrow.

New Approaches for Transplant Patients Linda J Burns, MD Medical Director, Health Services Research Program National Marrow Donor Program (NMDP)/Be the.

Hematopoietic Cell Transplantation Definition Hematopoietic cell transplantation (HCT) is a potentially curative treatment for malignant and nonmalignant.

Hematopoietic Stem-Cell Transplantation Edward A. Copelan, M.D. N Engl J Med 2006; 354: Review Article MEDICAL PROGRESS.

Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors N Engl J Med 2012;367: R3 Sunhee park/Prof. Kyung-sam cho.

Bone Marrow Transplant

Blood and Marrow Transplant: The basics…what you need to know

RIC UCBT Transplantation of Umbilical Cord Blood from Unrelated Donors in Patients with Haematological Diseases using a Reduced Intensity Conditioning.

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation

GVHD-Like Colitis in Renal Graft Recipient

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2010 CIBMTR Summary Slides INTRODUCTION: The Summary Slides are an annual report.

Tissue and Organ Transplantation

Transplantation Pathology

Supplemental table 1 Patients' characteristics Variables Number

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation

Current Uses and Outcomes of Hematopoietic Cell Transplantation (HCT)

Human Health and Disease

Allogeneic stem cell transplantation (allo-SCT) is a potentially curative procedure for a variety of malignant and nonmalignant conditions. Historically,

EBMT Activity Survey Teams 39,313 Patients 43,636 Transplants

EBMT Activity Survey Teams Patients Transplants

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients.

Transplantation Rejection of foreign tissue grafts is due to immune responses to alloantigens on the graft Blood group antigens Polymorphic MHC antigens.

Timing for HCT Consultation

Reduced-Intensity Allogeneic Stem Cell Transplantation in Adults and Children with Malignant and Nonmalignant Diseases: End of the Beginning and Future.

Blood and Lymphatic Systems

Re: Twenty-Year Follow-Up in Patients with Aplastic Anemia Given Marrow Grafts from HLA-Identical Siblings and Randomized to Receive Methotrexate/Cyclosporine.

Twenty Years of Unrelated Donor Bone Marrow Transplantation for Pediatric Acute Leukemia Facilitated by the National Marrow Donor Program Margaret L.

Should Methotrexate plus Calcineurin Inhibitors Be Considered Standard of Care for Prophylaxis of acute Graft-versus-Host Disease? Rainer Storb, Joseph.

Kasiani C. Myers, Stella M. Davies

Cutaneous Complications in Hematopoietic Cell Transplant Recipients: Impact of Biopsy on Patient Management Oana Paun, Tycel Phillips, Pingfu Fu, Roberto.

Post-Transplant Cyclophosphamide as Sole Graft-versus-Host Disease Prophylaxis Is Feasible in Patients Undergoing Peripheral Blood Stem Cell Transplantation.

Results of 10-Year Single Center Experience with Pharmacokinetics Directed Intravenous Busulfan, Cyclophosphamide and Etoposide Preparative Regimen in.

High Alloreactivity of Low-Dose Prophylactic Donor Lymphocyte Infusion in Patients with Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.

Introduction. Title: Activities and Outcomes of Hematopoietic Cell Transplantation in Japan.

Unrelated Stem Cell Transplantation after a Reduced Intensity Conditioning Regimen Containing High-Dose Thymoglobulin Leads to Controllable Graft-versus-Host.

Comparable Outcomes after HLA-Matched Sibling and Alternative Donor Hematopoietic Cell Transplantation for Children with Fanconi Anemia and Severe Aplastic.

Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation—A Similar.

HSCT in children with sickle cell Disease

Presentation transcript:

Bone Marrow Transplantation The transfer of living cells, tissues, or organs from a donor to a recipient, with the intention of maintaining the functional integrity of the transplanted material in the recipient

Just Names E.Donall Thomas George Santos vanBekkum George Mathe

Indications Acute and chronic leukemias Aplastic anemia Congenital immunodeficiency diseases Lymphomas Metabolic disease of childhood Myelodisplasia Thalassemia

Donor Limitations 25 – 30% of patients have an HLA-identical sibling. Marrow procured from unrelated living donor Marrow procured from related HLA-identical or HLA non –identical living donor Autologous transolantation(marroe procured during remession)

Recipient preparation Cyclophosphamide 60 mg/kg/day During two days and Toal body irradiation Busulfan 4mg/kg/day for fur days and Cyclophosphamide without irradiation Etoposide,Cyarabine as a maximizer antitumor properties,myeloblation,immunosuppression

Transplantation Procedure

Anesthesic Management Intravenouse anesthesia sould be procured. Intravenouse Thiopental,Fentanyl,Vecuronium can be used in common doses Maintanance can be provide with Propofol and Isoflurane.

Nota Bene Nitrouse Oxide should be avoided as an inactivator of Vit B12 wich is an essential coenzyme for methionine synthetase.This enzyme facilitate the conversion of homocystine and methyltetehydrofolate to methionine are essential for deoxyribonucleic acid (DNA) synthesis.

Complications Rejection by hte host of the marow graft Acute graft-vs,-host disease (GVHD) Infections Chronic GVHD Prolonged immunodeficiency Disease recurrence

Eugene Yevstratov MD Zacarias C.Vargas MD